MK-677 (Ibutamoren): Research Overview, Mechanism & Published Studies

MK-677 (Ibutamoren): Research Overview, Mechanism & Published Studies

Research Library entry. Updated August 2026.

Introduction to MK-677 research

MK-677, also called ibutamoren or MK-0677, is a small-molecule growth hormone secretagogue investigated in preclinical and clinical research. It was developed during efforts to identify orally active compounds that could engage the physiological growth-hormone secretagogue pathway. Unlike growth hormone itself, MK-677 is a non-peptide molecule. Its published literature has therefore been useful for examining how sustained stimulation of this pathway affects pulsatile growth hormone (GH) release, circulating insulin-like growth factor 1 (IGF-1), body-composition measurements, sleep architecture, and metabolic laboratory measures.

The nomenclature warrants a brief clarification. MK-677 and MK-0677 have both appeared in the literature and trial records for the same investigational compound; ibutamoren is its nonproprietary name. Some contemporary research records use the development name LUM-201 for ibutamoren mesylate. The scientific literature spans short pharmacology studies, randomized trials in older adults, studies of body composition, and trials in selected clinical research settings. These studies should be read in their individual design contexts: populations, endpoints, duration, and comparator conditions vary substantially.

This overview summarizes published MK-677 research; it is not a protocol, product-use guide, or medical resource. The most consistent human pharmacodynamic observation across the literature is stimulation of the GH/IGF-1 axis. Whether a biomarker shift translated into a particular functional endpoint has varied by study, and several trials did not show statistically significant differences in their primary clinical outcomes.

MK-677 mechanism of action

MK-677 is an agonist of the growth hormone secretagogue receptor, now generally called growth hormone secretagogue receptor type 1a (GHS-R1a). This G-protein-coupled receptor is the receptor through which the endogenous peptide ghrelin signals. GHS-R1a is expressed prominently in the hypothalamus and anterior pituitary, positions consistent with its role in neuroendocrine control of somatotroph activity.

In the anterior pituitary, receptor activation is associated with signaling that promotes GH release from somatotroph cells. At the hypothalamic level, the ghrelin receptor system interacts with growth hormone\u2013releasing hormone and somatostatin networks that help organize the pulsatile pattern of endogenous GH secretion. The resulting GH signal can in turn support hepatic and peripheral production of IGF-1; increased circulating IGF-1 is consequently a recurrent pharmacodynamic endpoint in ibutamoren research.

This is not simply a substitution for exogenous GH. The central and pituitary mechanism means the observed response depends on an intact secretagogue axis, endogenous secretory dynamics, feedback from IGF-1, and the study population. The work of Howard and colleagues identifying the ghrelin receptor provided an important molecular framework for interpreting the earlier growth-hormone secretagogue literature. In vitro receptor pharmacology and animal studies established that non-peptide secretagogues can act through this pathway; subsequent human investigations characterized the duration and downstream endocrine response to MK-677.

Ghrelin-receptor signaling is also relevant outside the pituitary. Ghrelin biology has connections to appetite regulation, glucose handling, sleep-related neuroendocrine rhythms, and energy balance. Those broader connections help explain why ibutamoren research commonly included appetite reports, body-composition measures, glucose and insulin assessments, and polysomnographic endpoints alongside GH and IGF-1 measurements. They do not, by themselves, establish a clinical outcome.

Published research summary

Growth hormone and IGF-1 research

Chapman et al. (1996, Journal of Clinical Endocrinology & Metabolism) examined daily oral MK-677 in healthy older adults. The investigators reported stimulation of the GH/IGF-1 axis that persisted during the study period, supporting the view that the compound remained pharmacodynamically active beyond a single administration. This study is frequently cited because it evaluated a population in which spontaneous GH secretion and IGF-1 concentrations are generally lower than in younger adults. It measured endocrine effects; it should not be treated as evidence for a particular health outcome.

In a later randomized, controlled trial, Nass et al. (2008, Annals of Internal Medicine) followed 65 healthy older adults for 12 months. Serum IGF-1 increased in the MK-677 group and remained elevated relative to placebo. The article describes an increase in GH secretion as well. The trial is particularly informative because it links the familiar endocrine endpoints to longer-duration observations, while also demonstrating that changes in GH/IGF-1 biomarkers do not resolve every question about clinical or functional outcomes.

Together, these controlled studies established MK-677 as an orally active ghrelin-receptor agonist with sustained GH-axis activity in the research settings studied. They also establish a useful evidence boundary: endocrine stimulation is a measured pharmacodynamic finding, whereas effects on composition, function, sleep, or metabolic outcomes require their own appropriately designed studies.

MK-677 body-composition studies

Body composition has been a major secondary area of MK-677 studies because the GH/IGF-1 axis is connected with lean mass, fat mass, total body water, and energy expenditure. Svensson et al. (1998, Journal of Clinical Endocrinology & Metabolism) studied obese men for two months. The investigators reported increased GH secretion and IGF-1, an increase in fat-free mass, and increased resting energy expenditure. Fat mass did not change significantly over the treatment interval. The distinction between fat-free mass and a direct measure of skeletal muscle is important: fat-free mass can reflect several compartments, including body water.

Nass et al. (2008) similarly reported increases in fat-free mass in healthy older adults. However, the trial did not find a statistically significant improvement in measures such as muscle strength or physical function compared with placebo. This combination of findings is an important interpretive lesson in MK-677 research: a compositional or biochemical measure is not interchangeable with a functional endpoint. The investigators also noted a rise in body weight in the active-treatment group, while total and visceral fat mass were not significantly different from placebo at one year.

Murphy et al. reported findings from diet-induced catabolism research that included changes in nitrogen balance and body-composition-related endpoints. These controlled research models were designed to characterize GH-secretagogue physiology under a catabolic challenge. Their results should be interpreted within that experimental design rather than generalized across unrelated populations or conditions.

Bone density and skeletal-marker research

The skeletal literature is more limited and more mixed than the endocrine literature. GH and IGF-1 have biologic relationships to bone turnover, so some MK-677 trials included bone mineral density (BMD) and biochemical turnover markers as exploratory or secondary endpoints. In the 12-month Nass et al. trial, bone mineral density was measured at several sites; the published report did not find a statistically significant difference in BMD between groups over the study interval. Markers of bone turnover changed in directions consistent with increased turnover, but these biomarker observations did not establish a BMD advantage within that trial.

Murphy et al. (1999, Journal of Bone and Mineral Research) pooled three randomized, double-blind, placebo-controlled studies lasting 2–9 weeks in 187 older adults. The investigators measured serum IGF-1, urinary N-telopeptide cross-links, osteocalcin, and bone-specific alkaline phosphatase. They reported increases in IGF-1 and in biochemical markers of both bone resorption and formation with MK-677. These are turnover markers, not direct measurements of fracture incidence, bone strength, or long-term BMD. The authors’ data therefore support a change in short-term skeletal remodeling markers under the study conditions, without establishing a clinical skeletal outcome.

Bach et al. and the MK-0677 Hip Fracture Study Group (2004, Journal of the American Geriatrics Society) conducted a multicenter randomized, double-blind, placebo-controlled study involving 161 previously mobile older people following hip fracture. Serum IGF-1 increased more in the MK-0677 group than in the placebo group. The authors did not find statistically significant group differences in the primary functional-performance measures or overall Sickness Impact Profile score. This is a valuable negative as well as positive result: it demonstrates a clear hormonal response without a conclusive functional effect in that specific trial. It was not a bone-density trial, but is often discussed alongside skeletal research because of its population and measured endpoints.

Overall, published MK-677 studies support continued interest in the GH/IGF-1\u2013bone-turnover relationship, but do not provide a uniform demonstration of improved BMD or function. Study duration, baseline characteristics, and endpoint selection remain central limitations when comparing reports.

Sleep-quality research

Sleep architecture is another area where GH-axis physiology and MK-677 mechanism of action intersect. Copinschi et al. (1997, Neuroendocrinology) used double-blind, placebo-controlled crossover designs in healthy young and older adults and assessed sleep with laboratory methods. In young participants, the higher studied exposure was associated with longer stage IV sleep and more rapid-eye-movement (REM) sleep than placebo. In the older cohort, the investigators reported increased REM sleep and reduced REM latency. The article characterized these as changes in sleep quality measures under the study conditions.

These findings are mechanistically interesting because the largest endogenous GH pulse is normally associated with early-night slow-wave sleep, and the investigators were studying a secretagogue that changes somatotropic activity. The study was small and short in duration. It describes polysomnographic observations, not an instruction for sleep management or a demonstration of long-term clinical benefit.

Metabolic studies

Metabolic endpoints require especially careful reading in ibutamoren research. GH secretion has counter-regulatory metabolic effects, and ghrelin-receptor signaling may affect appetite and insulin sensitivity. In the long-duration Nass et al. trial, fasting blood glucose increased and insulin sensitivity, assessed by a standard measure, decreased relative to placebo; mean glycated hemoglobin did not differ significantly between groups. The report also recorded increased appetite as an adverse event more often with MK-677. These data illustrate that GH/IGF-1 stimulation cannot be evaluated apart from glucose and insulin measurements.

The 2004 hip-fracture trial also collected metabolic laboratory measures and incorporated glucose-related eligibility and safety criteria. Like other trials in this area, it was not designed to turn a laboratory observation into broad guidance. It contributes to the pattern that metabolic monitoring was considered relevant in clinical development of the compound.

How to interpret the evidence. Across MK-677 studies, endocrine biomarkers, imaging or composition measures, subjective reports, polysomnography, and performance tests are distinct endpoint classes. An increase in IGF-1 is not a substitute for a functional measurement; a short-term change in a turnover marker is not a direct measure of BMD; and a small crossover sleep study is not a long-term outcome trial. This distinction is especially important when comparing studies with different ages, baseline physiology, duration, and statistical power. The literature is strongest where it directly measured GH-axis pharmacodynamics and less definitive for longer-term, patient-important outcomes.

More recently, a small Phase 2 study registered as NCT05364684 evaluated ibutamoren mesylate (LUM-201) using liver-fat quantification by proton magnetic resonance spectroscopy as a principal research endpoint. The registry lists the study as completed, with 12 enrolled participants and results posted. Registry information is useful for locating ongoing or recently completed research, but it should be distinguished from a peer-reviewed publication and interpreted only after examining the posted protocol and results.

Pharmacological profile

MK-677 is a synthetic, non-peptide, orally active ghrelin-receptor agonist. It is commonly supplied in research references as the mesylate salt, ibutamoren mesylate. The reported molecular formula for that salt is C₂₇H₃₆N₄O₅S, with a molecular weight of approximately 528.7 g/mol. Structurally, it is described as a spiroindoline-derived small molecule rather than a peptide, a feature relevant to its oral activity and to the historical distinction between peptide and non-peptide GH secretagogues.

Human studies characterize MK-677 as having a relatively long pharmacodynamic effect compared with the short plasma residence of some peptide secretagogues. Published pharmacokinetic discussions commonly report an elimination half-life in the range of approximately 4\u20136 hours, although reported values depend on the formulation, analytic method, participant characteristics, and study design. Pharmacodynamic consequences\u2014including GH pulses and IGF-1 changes\u2014follow their own time course and should not be conflated with a single plasma half-life value. Available work demonstrates oral bioavailability sufficient for clinical pharmacology research; this article deliberately does not provide administration or dosing information.

Safety considerations in research

Safety information in this section is factual reporting from clinical investigations, not medical advice. The number of exposed researchers, the populations studied, and study durations are limited relative to what would be needed to characterize all possible risks. Results from one population cannot be presumed to apply to another.

In the 2008 Nass et al. trial, the adverse events reported more frequently in the MK-677 group included increased appetite, mild lower-extremity edema, muscle pain, and elevations in fasting glucose. The investigators also reported decreased insulin sensitivity. Some edema and muscle-pain reports were generally mild and transient in that trial, but adverse-event descriptions do not establish an individual risk profile. The same publication reported that fasting glucose changes were most apparent early in the study and subsequently stabilized, while glucose-related measures remained a focus of observation.

Earlier studies and the hip-fracture trial similarly incorporated safety surveillance and laboratory monitoring. Across the literature, appetite-related effects, fluid-retention-type observations, musculoskeletal complaints, and glucose/insulin changes are recurring topics. The association of MK-677 with GH and IGF-1 stimulation also means that endocrine feedback and metabolic context are intrinsic to its pharmacology. A research summary should not convert those observations into an assumption of safety, efficacy, or suitability for any person.

Current research status

MK-677 remains a research compound with a substantial historical clinical-pharmacology literature but a limited body of large, contemporary, peer-reviewed outcome trials. Its best-established published observations concern ghrelin-receptor agonism and increases in GH and IGF-1. Research on body composition, sleep architecture, bone-related endpoints, and metabolism has generated signals that are context-specific and, in several studies, not matched by statistically significant functional outcomes.

Trial registries identify recent work under the names ibutamoren, MK-0677, and LUM-201. Registry status is time-sensitive: for example, NCT05364684 was listed as completed and updated in January 2026 when this overview was prepared. A registry listing does not itself constitute peer review, and a completed study does not necessarily resolve an endpoint until its data are independently assessed. Future research that uses transparent designs, appropriate comparators, longer follow-up, and prespecified functional and metabolic endpoints will be most useful for clarifying the significance of the established endocrine pharmacology.

Research-use-only notice

For research and informational purposes only. This Research Library article summarizes published literature and does not provide medical advice, diagnosis, treatment recommendations, dosing, or instructions for human use. Research compounds are not intended for use in humans or animals outside appropriately authorized research. Iron Peak Peptides products are sold for research use only and are not offered to diagnose, treat, cure, or prevent any disease.

References

1. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974\u2013977. doi:10.1126/science.273.5277.974.
2. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone/insulin-like growth factor I axis by daily oral administration of a growth hormone secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996;81:4249\u20134257.
3. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278\u2013286. doi:10.1159/000127249. PMID:9349662.
4. Svensson J, L\u00F6nn L, Jansson JO, et al. Two months of treatment with the oral growth hormone secretagogue MK-677 increases growth hormone secretion, fat-free mass, and energy expenditure in obese men. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362\u2013369.
5. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research. 1999;14(7):1182–1188. doi:10.1359/jbmr.1999.14.7.1182. PMID:10404019.
6. Bach MA, Rockwood K, Zetterberg C, et al.; MK 0677 Hip Fracture Study Group. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. Journal of the American Geriatrics Society. 2004;52(4):516\u2013523. doi:10.1111/j.1532-5415.2004.52156.x. PMID:15066065.
7. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9):601\u2013611. doi:10.7326/0003-4819-149-9-200811040-00003. PMCID:PMC2757071.
8. ClinicalTrials.gov. The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease. Identifier NCT05364684. Massachusetts General Hospital. Accessed August 2026.